Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma

Treatment of high-risk neuroblastoma typically incorporates multiagent chemotherapy, surgery, radiation therapy, autologous stem cell transplantation, immunotherapy, and differentiation therapy. The discovery of activating mutations in ALK receptor tyrosine kinase (ALK) in ∼8% of neuroblastomas open...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tingting, Merguerian, Matthew D., Rowe, Steven P., Pratilas, Christine A., Chen, Allen R., Ladle, Brian H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2021
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327881/
https://www.ncbi.nlm.nih.gov/pubmed/34210658
http://dx.doi.org/10.1101/mcs.a006064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327881/
https://www.ncbi.nlm.nih.gov/pubmed/34210658
http://dx.doi.org/10.1101/mcs.a006064

Ejemplares similares